Sort
82,697 grants matching “vaccine development”
Predicting immune responses that correlate with protection against tuberculosis
$1,211,784Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · HL
Vaccine and adjuvant Clinical GMP product development and DNA Technology platform enhancements
$1,211,603Trevor Smith · Wistar Institute · U19 · FY2024 · AI
Frontiers: University of Kansas Clinical and Translational Science Institute
$1,211,546Mario Castro · University Of Kansas Medical Center · UL1 · FY2021 · TR
Tularemia: Pathogenesis and Host Response
$1,211,423Karl E Klose · University Of Texas San Antonio · P01 · FY2006 · AI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine
$1,211,368Axel T Lehrer · University Of Hawaii At Manoa · R01 · FY2021 · AI
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever
$1,210,843Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2019 · AI
Pulmonary innate immune activation for bioterror defense
$1,210,843Coley Pharmaceutical Group, Inc. · U01 · FY2003 · AI
Development of Inhaled CPZEN-45 For Tuberculosis Therapy
$1,210,721Diana M Severynse-Stevens · Research Triangle Institute · R01 · FY2022 · AI
Biophysical Membrane Mechanisms of Exocytosis inside Extracellular Vesicles, Membrane Repair Failing in Muscular Dystrophy, and Parasite Replication
$1,210,393Joshua Zimmerberg · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2025 · HD
HIV vaccine swarms for PWID
$1,210,300Pablo Penaloza · Beth Israel Deaconess Medical Center · DP1 · FY2025 · DA
Antigen Processing And Presentation In The Intestine
$1,210,048Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Vanderbilt HIV Clinical Trials Unit
$1,209,774David W Haas · Vanderbilt University · UM1 · FY2013 · AI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine
$1,209,712Axel T Lehrer · University Of Hawaii At Manoa · R01 · FY2019 · AI
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
$1,209,546Andrea L Cox · Johns Hopkins University · U19 · FY2022 · AI
IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTION
$1,209,516University Of Colorado Denver · U01 · FY2000 · AI
Mechanism of action and therapeutic utility of immunostimulatory CpG oligonucleo
$1,209,238Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Novel vaccine candidates for Y. pestis from genomics
$1,209,134Chiron S.R.L. · U01 · FY2004 · AI
Units for HIV/AIDS Clinical Trials Networks
$1,208,979Ram Yogev · Lurie Children'S Hospital Of Chicago · UM1 · FY2013 · AI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses
$1,208,817John H Eldridge · Profectus Biosciences, Inc. · R01 · FY2016 · AI
Structure-based design of novel Lassa virus glycoproteins for vaccine development
$1,208,740Robert F Garry · Tulane University Of Louisiana · R01 · FY2018 · AI
Modulation of Biodefense Responses to Bacterial Pathogen
$1,208,717University Of Connecticut Sch Of Med/Dnt · P01 · FY2005 · AI
Program in Systems Immunology and Infectious Disease Modeling
$1,208,653Ronald Germain · Niaid Extramural Activities · Z01 · FY2007 · AI
Preclinical Development of Flagellin as a Mucosal Adjuvant in Biodefense Vaccines
$1,208,308Steven B. Mizel · Wake Forest University Health Sciences · U01 · FY2006 · AI
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,208,302Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Human Immune Monitoring Core
$1,207,964Holden T. Maecker · Stanford University · P01 · FY2025 · AI